MindRank AI Receives Recognition as 2024 Hangzhou Municipal High-Tech Enterprise R&D Center

The Enterprise High and New Technology Research and Development Center is a relatively independent research and development institution established within an enterprise. It serves as a crucial innovative force to promote technological innovation, the transformation of achievements, and enhance the core competitiveness of enterprises. This is "MindRank" in the selection.Zhejiang Province Science and Technology Small and Medium-sized Enterprises, Hangzhou "Eagle Plan" Enterprise, Hangzhou Innovative Small and Medium-sized EnterprisesAnother important government qualification obtained, the company's technical R&D strength, independent innovation capability, and achievement transformation have once again received official recognition.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company’s vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.

The AI pharmaceutical solution of MindRank Ltd. was rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was included in Forbes' "Forbes Asia 100 to Watch" list, with only 11 start-up companies from mainland China making the list.

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai